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graphed ECV—15% total body volume. Patients are on a cardiac
monitor and observed during the 3–5 hour treatment. ECP is
performed 2 days in a row. Initially, we started every other week
and now have moved to starting weekly as we have noticed faster
improvement with this schedule. As symptoms improve, ECP
schedule is tapered. Seven patients have been treated (median age
13 years (9–28), 4 males/3 females). Median duration of ECP: 11
months (1–26). The procedure is well tolerated with mild symp-
toms of hypovolemia noted in patients 25 kg. Weight at start of
ECP was median 48 kg (22.2–79). Patients 25 kg have received
about 1 pRBC transfusion/month. All patients had failed standard
therapy with cyclosporine and prednisone in addition to a second-
or third-line agent. All were on prednisone at start of treatment.
Two patients have renal insufﬁciency. An attempt to lower pred-
nisone dose and discontinue other immunosuppression was made
after stabilization of cGVHD. Three patients expired due to
cGVHD complications. Of the remaining 4 patients: 1 is too early
to evaluate, all 3 others have responded, of which 2 have discon-
tinued steroid therapy. Response by organ and steroid doses are
listed below. All patients remain on a tapered schedule of ECP
(every 3 or 4 weeks) since ECP discontinuation led to cGVHD
ﬂares in 2, which responded with reinstitution of ECP. The pa-
tients with scleroderma and oral sensitivity appear to have had
signiﬁcant beneﬁt from ECP. ECP is feasible in pediatric patients
with cGVHD if hct and hydration are carefully maintained at
adequate levels for lower-weight patients. ECP appears to be
efﬁcacious for refractory cGVHD. Prospective studies are needed
to deﬁne treatment duration and schedule, and beneﬁts of using
ECP concurrently with other immunosuppressants. Finally, we
plan on demonstrating feasibility in patients20 kg using a similar
algorithm (Table 1).
Table 1. Pediatric Patients with Refractory CGVHD Treated with
Extracorporeal Photopheresis
Age
(yrs)
Duration
(mos)
Symptoms
at Diagnosis
Most
Recent
Symptoms
Intital and
Most
Recent
PDN
Dose, mg/
kg/d
Line
Type Outcome
Weight at
ECP Start
(kg)
12 7 Eyes,
mouth,
skin >
50%
Eyes-SD.
mouth-
CR, Skin-
PR
2 3 0.6 10F Double
Lumen
CVL
Dead 28.6
18 20 Liver Liver-CR 1.6 3 0 10 F single
lumen
CVL
Alive and
Well
48
20 11 Mouth, Skin
> 75%,
Liver
Mouth-PR,
skin-PR,
Liver-PD
0.5 3 0.5 9.6 F
Vortex
Port
Dead 79
11 3 Pulmonary Pulmonary-
PD
1 3 0.5 10 F
Double
Lumen
CVL
Dead 26
28 26 Skin > 50%
(Scleroderma)
Skin-PR 1 3 0.25 9.6 F
Vortex
port
Alive and
well
60.6
9 14 Skin > 50%
(Scleroderma)
Skin-PR 1 3 0 5 F Yuey
PIV
Placed
Before
Each
ECP
Alive and
Well
22.2
13 1 Liver Too Early
to
Evaluate
1 3 0.67 12 F
Double
Lumen
CVL
Alive and
Well
61.5
SD  stable disease, CR  complete response, PR  partial
response, PD  progressive disease, PDN  prednisone,
%body surface area.
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GRAVES’ DISEASE FOLLOWING UNRELATED UMBILICAL CORD BLOOD
TRANSPLANTATION IN PEDIATRIC PATIENTS
Driscoll, T.A.1, Ciocci, G.H.1, Kurtzberg, J.1 Pediatric Blood & Marrow
Transplant Program at Duke University Medical Center, Durham, NC.
Graves’ disease (GD) is the most prevalent autoimmune disease
in the United States with a peak incidence in the ﬁfth to sixth
decades of life and a female to male predominance of 10:1. In
recipients of allogeneic bone marrow and peripheral blood stem
cell transplants, GD recurs in previously affected recipients, occurs
in unaffected recipients by adoptive transfer of autoimmune thy-
roiditis from an affected donor, and occurs less frequently in
unaffected recipients transplanted with unaffected donors. GD was
diagnosed through laboratory surveillance in 3 male pediatric pa-
tients ages 5.5–14.3 years, 30–60 months after UCBT. All 3
affected patients received grafts from female donors and were full
donor chimeras. None had graft-versus-host disease (GvHD) at
diagnosis with GD. Two were transplanted for metabolic diseases
(ALD, PNP deﬁciency) and 1 for ALL. All were conditioned with
busulfan/ATG  cyclophosphamide (n  2) or melphalan (n  1)
and received cyclosporine and methylprednisolone for prophylaxis
against GvHD. All were off immunosuppression therapy for 	1
year at diagnosis of GD. Treatment with readioactive iodide (n 
2) and Propylthiouracil (n 1) corrected laboratory abnormalities.
The 3 boys were part of a cohort of 265 patients transplanted at our
center between 9/1993 and 9/2004, surviving for 	1 year post
UCBT. Within this group, 55% of the patients had female donors
and 45% had male donors. Interestingly, the three cases of GD
occurred among the 86 male patients who received female-donor
UUCBTs. No cases of GD were seen in female recipients. Neither
the donors nor mother of donors developed autoimmune diseases.
However, given their young ages, absence of disease does not rule
out the possibility of development of this disease several decades
into the future.The development of GD in 3 boys after UCBT
from female donors is interesting. The etiology of Graves’ Disease
remains incompletely understood but genetic susceptibility con-
tributes to the development of disease. One affected patient and its
donor expressed the GD susceptibility allele, HLA-DRB10301,
and conversely, a second affected patient and its donor expressed
the GD protective allele, DRB10701. This could indicate the
presence of other immunologic tendencies towards autoimmune
disease in the cord blood donor or an alloreactive process from
donor or low levels of maternal donor cells contaminating the
UCB graft. Further studies will be necessary to determine the
etiology of GD in these patients.
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RISK FACTORS FOR DEVELOPMENT OF SYMPTOMS AFTER AUTOLO-
GOUS TRANSPLANTATION FOR MULTIPLE MYELOMA
Campagnaro, E.1, Saliba, R.1, Anderson, K.1, Roden, L.1, Mendoza, F.1,
Aleman, A.1, Cleeland, C.1, Weber, D.1, Brown, J.1, Giralt, S.1 Blood
and Marrow Transplantation, University of Texas M.D. Anderson
Cancer Center, Houston, TX.
Background: Multiple myeloma (MM) is the most common
indication for autografting in the United States. Although safe,
autografting can be associated with substantial morbidity due to
the toxic side effects of chemotherapy. Strategies aimed at mini-
mizing symptoms post autografting may result in better tolerance.
The risk factors for symptom development post autografting for
MM have not been well characterized. Purpose: To deﬁne pre-
transplant conditions, which may be predictive of post-transplant
symptom burden.Methods:We performed prospective evaluation
of symptom burden among 64 myeloma patients undergoing au-
tograft at MDACC as well as retrospective review of pretransplant
variables including patient demographics, performance status, al-
bumin, disease status, and Charlson Comorbidity Index (CCI).
Univariate analysis was performed to correlate pretransplant vari-
ables with post transplant symptom burden as deﬁned by M. D.
Anderson Symptom Inventory (MDASI) scores at different time
points post transplant. Results: 64 patients were studied from
6/2000 to 5/2003. Symptom burden increased from baseline to day
0 to nadir, with most patients returning to their baseline by day 30
post transplant. Table 1 summarizes the potential impact of pre-
transplant variables on median MDASI scores at nadir. Patients
with the highest MDASI scores at baseline had the highest MDASI
scores at nadir in quartile analysis (P  .001). Patients with Charl-
son score of 3, age 	 60, 2 microglobulin (2M) 	 3, albu-
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